2-year follow-up of trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer: a randomised controlled trial
Ian Smith(Institute of Cancer Research), Marion Procter(Frontier Agriculture (United Kingdom)), Richard D. Gelber(Dana-Farber Cancer Institute), Sébastien Guillaume(Institut Jules Bordet), A. Feyereislova(Roche (Switzerland)), Mitch Dowsett(Institute of Cancer Research), Aron Goldhirsch(European Institute of Oncology), Michael Untch(Klinik für Frauenheilkunde), Gabriella Mariani(Fondazione IRCCS Istituto Nazionale dei Tumori), José Baselga(Vall d'Hebron Hospital Universitari), Manfred Kaufmann(Goethe University Frankfurt), David Cameron(Western General Hospital), Richard H. Bell(Geelong Hospital), Jonas Bergh(Karolinska University Hospital), Robert L. Coleman(Weston Park Cancer Centre), Andrew Wardley(The Christie Hospital), Nadia Harbeck(Klinikum rechts der Isar), R.I. Lopez(National Oncologic Institute), Peter Mallmann(University Hospital Cologne), Karen A. Gelmon(BC Cancer Agency), Nicholas Wilcken(Westmead Hospital), Erik Wist(Oslo University Hospital), Pedro Sánchez‐Rovira(Complejo Hospitalario de Jaén), Martine Piccart(Université Libre de Bruxelles)
Cited by 1,511
Abstract
Related Papers
No related papers found
Powered by citation graph analysis